Retinal Disease Treatment: Advances in Anti-VEGF & Diabetes Meds

WAIKOLOA, Hawaii — Advances in treatments for retinal diseases are gaining momentum, with emerging data suggesting that newer therapies and even medications commonly used for diabetes could significantly impact patient outcomes. At Retina 2026, Ehsan Rahimy, MD, a retina specialist at Palo Alto Medical Foundation, highlighted encouraging findings related to extended-duration anti-VEGF therapies and the potential role of GLP-1 receptor agonists in managing diabetic eye disease.

The discussion centered on a shift towards more durable treatments for neovascular age-related macular degeneration (AMD), a leading cause of vision loss. Recent real-world data, published throughout 2025, indicates that switching patients who haven’t fully responded to existing anti-VEGF treatments to next-generation options like Eylea HD (aflibercept 8 mg, Regeneron) can lead to extended intervals between injections. This study demonstrated promising results in extending treatment intervals.

“I’ve been encouraged to see that patients on average have been able to extend treatment intervals out to about 2 to 3 weeks additional for… neovascular [age-related macular degeneration],” Rahimy told Healio. “That can make all the difference for some of these patients if it’s one or two less office visits a year.” Anti-VEGF (vascular endothelial growth factor) therapies operate by blocking the growth of abnormal blood vessels in the eye, a hallmark of wet AMD and other retinal conditions. Reducing the frequency of injections can improve patient convenience and potentially reduce treatment-related side effects, though long-term outcomes are still being evaluated.

Diabetes Medications and Retinal Health: An Emerging Connection

Beyond advancements in anti-VEGF therapies, a growing body of evidence suggests a potential link between GLP-1 receptor agonists – a class of medications primarily used to treat type 2 diabetes – and improved outcomes in diabetic retinopathy and diabetic macular edema. Research published in November 2025 indicated that GLP-1s may even influence the risk of developing wet AMD, though the exact mechanisms are still under investigation.

GLP-1 receptor agonists work by mimicking the effects of a natural hormone that regulates blood sugar levels. They have been shown to improve glycemic control, promote weight loss and potentially offer cardiovascular benefits. The connection to retinal health is thought to be related to the drugs’ impact on vascular function and inflammation, both of which play a role in the development and progression of diabetic eye disease. Though, it’s important to note that the findings are still preliminary and require further investigation.

“Real-world studies are going to be increasingly important to rely on to see how these types of drugs are affecting the population,” Rahimy emphasized. Real-world data, collected from routine clinical practice, can provide valuable insights into the effectiveness and safety of treatments in diverse patient populations, complementing the findings from controlled clinical trials.

Understanding the Limitations and Next Steps

Whereas the initial findings are promising, it’s crucial to acknowledge the limitations of the current evidence. Many of the studies are observational, meaning they can demonstrate associations but cannot prove cause-and-effect relationships. Confounding factors, such as differences in patient demographics, disease severity, and other medical conditions, could potentially influence the observed outcomes. The long-term effects of these therapies on retinal health remain unknown.

The U.S. Food and Drug Administration (FDA) and other regulatory agencies continuously monitor emerging data on drug safety and efficacy. As more real-world evidence becomes available, guidelines for the management of retinal diseases may be updated to reflect the latest findings. Ongoing clinical trials are also investigating the potential benefits of GLP-1 receptor agonists and other novel therapies for diabetic retinopathy and AMD. The NRC also provides updates on events related to radiation control, which can impact medical treatments.

For individuals with retinal diseases, it’s essential to maintain regular follow-up appointments with a qualified ophthalmologist or retina specialist. Early detection and timely treatment are crucial for preserving vision and preventing disease progression. Patients should discuss any concerns or questions they have about their treatment options with their healthcare provider.

The Emergency Email Network (emergencyemail.org) provides updates on public health emergencies, which can be relevant to accessing healthcare services. Staying informed about potential disruptions and following the guidance of public health officials can assist ensure continuity of care.

Looking ahead, the field of retinal disease treatment is poised for continued innovation. Researchers are exploring new drug delivery systems, gene therapies, and other cutting-edge approaches to address the underlying causes of vision loss. The convergence of advancements in pharmacology, technology, and data science holds the promise of transforming the lives of millions of people affected by these debilitating conditions. You can also stay up to date on Congressional activity related to healthcare through Congress.gov.